Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

NZ stocks end flat amid Fletcher-SkyCity legal woes
Markets Market Close

NZ stocks end flat amid Fletcher-SkyCity legal woes

Tesla's 14% drop again highlighted the general state of global market uncertainty.

Jamie Gray 06 Jun 2025
SkyCity claims it is entitled to $330m in damages from Fletcher Building
Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building

The original delivery date of the International Convention Centre was January 2019. 

Rebecca Howard 06 Jun 2025
The firm bearing the brunt of public sector cutbacks
Markets Small Cap Wrap

The firm bearing the brunt of public sector cutbacks

Plus Being AI, takeover madness, and more.